| Neuromyelitis Optica Spectrum Disorder |
ChiCTR-OPB-16007730: Mycophenolate Mofetil Treatment of Neuromyelitis Optica in Chinese Patients (MONICA) |
|
|
| Recruiting | 4 | 100 | | Mycophenolate Mofetil | The third affiliated hospital, Sun Yat-sen university; The third affiliated hospital, Sun Yat-sen university, Manufacturer of sponsorship | Neuromyelitis optica | | | | |
ChiCTR1900025744: Clinical effectiveness and safety of Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial |
|
|
| Recruiting | 4 | 60 | | Intravenous 200mg Rituximab, 1/week*2, if the proportion of CD19+ B lymphocytes in peripheral blood is above 1% then repeat administration (200mg) ;Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (750～3000mg/day) | The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital; The General Hospital of Chinese Peoples Liberation Army, funded by the National Natural Science Fundation of China (NO.81870662) | neuromyelitis optica spectrum disorder （NMOSD） | | | | |
NCT05896605: Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder |
|
|
| Completed | 4 | 63 | RoW | Azathioprine, Azathioprine Tablets | First Affiliated Hospital of Guangxi Medical University | NMO Spectrum Disorder, Azathioprine Adverse Reaction | 12/22 | 04/23 | | |
| Terminated | 4 | 4 | Europe, Canada, Japan, US, RoW | Satralizumab 120 mg | Hoffmann-La Roche, Chugai Pharmaceutical Co. | Neuromyelitis Optica Spectrum Disorder, NMOSD | 10/23 | 10/23 | | |
ChiCTR2100043013: Efficacy difference between low dose rituximab and mycophenolate mofetil in preventing recurrence of NMOSD |
|
|
| Not yet recruiting | 4 | 60 | | low dose rituximab ;mycophenolate mofetil | Shandong University Qilu Hospital; Shandong University Qilu Hospital, self-finance | Neuromyelitis optica spectrum diseases | | | | |
NCT06212245: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | 4 | 33 | RoW | Inebilizumab | Hansoh BioMedical R&D Company, Horizon Therapeutics Ireland DAC | Neuromyelitis Optica Spectrum Disorders | 12/24 | 06/25 | | |
| Recruiting | 4 | 30 | Europe, RoW | Blood tests, Inebilizumab, UPLIZNA | Amgen | Neuromyelitis Optica Spectrum Disorder | 06/28 | 06/28 | | |
ChiCTR2400086835: Ofatumumab for the treatment of optic neuritis associated with neuromyelitis optica spectrum disorder |
|
|
| Recruiting | 4 | 10 | | hypodermic injection(the individual group accept 20mg ofatumumab subcutaneously once a week in week 0, week 2 of the first month, and the B lymphocyte subsets were detected every month after that. Supplementary injection was performed when CD19+B lymphocytes close to the target value 1%) | Chinese PLA General Hospital & Chinese PLA Medical School; Chinese PLA General Hospital & Chinese PLA Medical School, self-financing | optic neuritis associated with neuromyelitis optica spectrum disorder | | | | |
ChiCTR2400087203: Clinical Study of Inebilizumab Combined with Steroids for the Treatment of Neuromyelitis Optica Spectrum Disorder |
|
|
| Recruiting | 4 | 128 | | After acute steroid pulse therapy, switch to oral prednisone 60mg once daily for tapering, reducing by 10mg per week. Discontinue prednisone two weeks after the second dose of inebilizumab, and follow up observation until week 48 (combined use of inebilizumab and steroids for 1 month).; After the acute phase hormone shock, switch to oral prednisone 60mg once daily for tapering, decrease by 10mg every week until reaching 10mg once daily for maintenance for a month, then further taper to 10mg every other day until the third month, and discontinue enalapril after continuous follow-up observation for 48 weeks (enalapril with hormones for a total of 6 months). | West China Hospital,Sichuan University; West China Hospital,Sichuan University, The Foundation | neuromyelitis optica spectrum disorders | | | | |
